Ultimovacs – executive interview Test

Ultimovacs – executive interview Test

Ultimovacs — 7 videos in collection

More on this equity

Ultimovacs is a Scandinavian-based biotech focused on developing novel immunotherapies in combination with checkpoint inhibitors against cancer. Its lead product candidate, UV1, is a universal off-the-shelf peptide-based vaccine being studied in ongoing Phase II clinical trials across five indications. The innovative oncology vaccine targets the cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of settings and would increase accessibility.

In this interview, Ultimovacs CMO Jens Bjørheim recaps the company’s progress and provides a preview of the upcoming rich newsflow.

You may also be interested in these:


Ultimovacs – executive interview



Ultimovacs - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free